Ready Or Not: FDA Accepting Adaptive Trial Applications
This article was originally published in Pharmaceutical Approvals Monthly
Who will have access to unblinded clinical trial data and what that structure would look like is one of the biggest adaptive trial issues yet to be hammered out between FDA and industry, FDA officials said.
You may also be interested in...
Using an adaptive trial design, Cell Therapeutics uncovered a better than anticipated interim response rate in its Phase III EXTEND study of pixantrone in aggressive non-Hodgkin’s lymphoma.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011